title: [Neoadjuvant hormonal therapy for prostate cancer].
abstract: Preoperative neoadjuvant hormonal therapy is still controversial. This therapy's purpose is downstaging prostate cancer at radical prostatectomy and thereby improving the prognosis of prostate cancer. It has been repeatedly demonstrated that hormonal therapy causes significant alterations in the gross and microscopic appearance of the prostate. Most studies report a significant improvement in surgical margins and downstaging. However, it remains to be seen if the favorable findings lead to an improved outcome after radical prostatectomy. Our study showed 6-12 months neoadjuvant hormonal therapy with maximal androgen blockade did not lead to the improved result in long term follow-up. Because, PSA failure was observed 25% of the cases which received neoadjuvant hormonal therapy prior to radical prostatectomy.
authors.affiliation: Department of Urology, School of Medicine, Tokai University.
authors.forename: Hideshi
authors.initials: H
authors.lastname: Miyakita
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D005485:Flutamide / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide; D017430:Prostate-Specific Antigen